JC04 Rec'd PCT/PTO 05 AUG 2005

OIPE JC14 AUG 05 2005 PATENT & TRADEMARK OFFICE

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 3, 2005 Signature: Denise Kacinski
(Denise Kacinski)

Docket No.: 62052(51588)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Mark C. Poznansky et al.

Application No.: 10/537,610 Confirmation No.: Unknown

Filed: June 3, 2005 Art Unit: N/A

For: METHODS AND COMPOSITIONS RELATING TO GRADIENT EXPOSED CELLS Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be

an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 62052(51588). A duplicate copy of this paper is enclosed.

Dated: August 3, 2005

Respectfully submitted,

By _____
Amy M. Leahy
Registration No.: 47,739
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, MA 02205
(203) 975-7505
Attorneys/Agents For Applicant

OIPE JC145
AUG 0 5 2005
PAT & TRADEMARK OFFICE

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/537,610
Filing Date	June 3, 2005
First Named Inventor	Mark C. Poznansky
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	62052(51588)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-20020131953	09/19/2002	Takashima et al.	
	AB	US-6,448,054	09/10/2002	Poznansky et al.	
	AC	US-6,399,569	06/04/2002	Cohen et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	CA	SUZUKI et al. "Diverse Transcriptional Response of CD4+ T Cells to Stromal Cell-Derived Factor (SDF)-1: Cell Survival Promotion and Priming Effects of SDF-1 on CD4+ T Cells." The Journal of Immunology (2001), 167: 3064-3073	
	CB	STAUDT et al. "Genomic Views of the Immune System." Annu. Rev. Immunol. (2000), 18:829-859	
	CC	LASTER et al. "Target-induced changes in macrophage migration may explain differences in lytic sensitivity among simian virus 40-transformed fibroblasts." J. Immunol. (1988) July 1: 141(1):221-7	
	CD	GURDON et al. "Morphogen gradient interpretation." Nature (2001) 413(6858):797-803	
	CE	DYSON et al. "The interpretation of position in a morphogen gradient as revealed by occupancy of activin receptors." Cell (1998) 93(4): 557-68	
	CF	MCDOWELL et al. "Formation of a functional morphogen gradient by a passive process in tissue from the early Xenopus embryo." Int. J. Dev. Biol. (2001) 45(1 Spec No): 199-207	
	CG	CADIGAN "Regulating morphogen gradients in the Drosophila wing." Semin Cell Dev Biol (2002) 13(2): 83-90	
	CH	SHIMIZU et al. "A quantitative analysis of signal transduction from activin receptor to nucleus and its relevance to morphogen gradient interpretation." Proc Natl Acad Sci USA (1999) 96(12): 6791-6	
	CI	MCDOWELL et al. "Activin has direct long-range signalling activity and can form a concentration gradient by diffusion." Curr Biol (1997) 7(9): 671-81	
	CJ	RYAN et al. "The Xenopus eomesodermin promoter and its concentration-dependent respons to activin." Mech Dev (2000) 94(1-2): 133-46	
	CK	TEMARU et al. "High glucose enhances the gene expression of interleukin-8 in human endothelial cells, but not in smooth muscle cells: possible role of interleukin-8 in diabetic macroangiopathy." Diabetologia (1997) 40(5): 610-3	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/537,610
Filing Date	June 3, 2005
First Named Inventor	Mark C. Poznansky
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	62052(51588)

	CL	TONETTIi et al. "Neutrophil migration into the gingival sulcus is associated with transepithelial gradients of interleukin-8 and ICAM-1." J. Periodontol (1998) 69(10): 1139-47	
	CM	BRAISTED et al. "graded and lamina-specific distributions of ligands of EphB receptor tyrosine kinases in the developing retinotectal system." Dev Biol (1997) 191 (1): 14-28	
	CN	CHRISTOPHERSON et al. "Transgenic overexpression of the CC chemokine CCL21 disrupts T-cell migration." Blood (2001) 98(13): 3562-8	
	CO	TURNER et al. "Hypoxia inhibits macrophage migration." Eur J Immunol. (1999) 29(7): 2280-7	
	CP	JANOWSKA-WIECZOREK et al. "Differential MMP and TIMP production by human marroe and peripheral blood CD34(+) cells in response to chemokines." Exp Haematol (2000) 28(11): 1274-84	
	CQ	NELLEN et al. "Direct and long-range action of a DPP morphogen gradient." Cell (1996) 85(3): 357-68	
	CR	CAMPBELL et al. "Transducing the Dpp morphogen gradient in the wing of Drosophilia: regulation of Dpp targets by brinker." Cell (1999) 96(4): 553-62	
	CS	GRIMM et al. "Control of the gene optomotor-blind in Drosophilia wing development by decapentaplegic and wingless." Science (1996) 271(5255): 1601-4	
	CT	JAZWINSKA et al. "The Drosophilia gene brinker reveals a novel mechanism of Dpp target gene regulation." Cell (1999) 96(4): 563-73	
	CU	STAEHLING-HAMPTON et al. "Dpp induces mesodermal gene expression in Drosophilia." Nature (1994) 372(6508): 783-6	
	CV	KIECKER et al. "A morphogen gradient of Wnt/beta-catenin signalling regulates anteroposterior neural patterning in Xenopus." Development (2001) 128(21): 4189-201	
	CW	PAPAGEORGIOU "A physical force may expose Hox genes to express in a morphogenetic density gradient." Bull Math Biol (2001) 63(1): 185-200	
	CX	TOMOYASU et al. "The decapentaplegic morphogen gradient regulates the notal wingless expression through induction of pannier and u-shaped in Drosophilia." Mech Dev (2000) 96(1): 37-49	
	CY	GURDON et al. "Single cells can sense their position in a morphogen gradient." Development (1999) 126(23):5309-17	
	CZ	GURDON et al."An experimental system for analyzing response to a morphogen gradient." Proc. Natl. Acad. Sci. USA (1996) 93: 9334-9338	
	CA1	BAO et al. "Temporal Gradient in Shear but not Steady Shear Stress Induces PDGF-A and MCP-1 Expression in Endothelial Cells." Arterioscler Thromb Vasc Biol. (1999) 19: 996-1003	
	CB1	RUTHISHAUSER et al. "T-Cells differentially express genes encldng molecules involved in chemokine signal transduction when migrating towards or away from gradients of SDF-1(CXCL12) Abstract, January 7, 2003	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	

OIPE JC145
AUG 0 5 2005
PAT'T & TRADEMARK OFFICE

PTO/SB/92 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/537,610 Attorney Docket No.: 62052(51588)

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on August 3, 2005 .
Date

Denise Kacinski
Signature

Denise Kacinski
Typed or printed name of person signing Certificate

Registration Number, if applicable

(203) 975-7505
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (32 References) (2 pages)
Information Disclosure Statement